Important news from Molteno Ophthalmic Ltd - 6th Jul 2020

Important news from Molteno Ophthalmic Ltd Molteno Ophthalmic Ltd is delighted to announce that Nova Eye Medical Inc has acquired Molteno Ophthalmic’s assets, with settlement expected on 31 July 2020. Nova Eye Medical is an Australian listed company, formerly part of Ellex. The company was renamed after the recent sale of the Ellex laser and ultrasound division. The purchase issues in an exciting new era for Molteno Ophthalmic Ltd (MOL) as it moves from private ownership to become part of Nova Eye Medical.
Founders of Molteno Ophthalmic, Tess and Ant Molteno, expressed their appreciation of the loyal and dedicated MOL staff who have been with the company through many changes and challenges and continue to manufacture the Molteno and Molteno3® glaucoma implants according to the highest international quality standards.
                     
With the acquisition, Nova Eye Medical will be able to offer ophthalmologists a portfolio of treatment technologies that cover all stages of the glaucoma disease process from the iTrack Surgical System for mild-moderate glaucoma to the Molteno3® Glaucoma Drainage Devices (GDDs) for severe or complex cases.
                  
The immediate benefit for Molteno Ophthalmic distributors and customers will be improved marketing and training for the Molteno3® GDDs. Despite offering enhanced surgical utility and optimized clinical outcomes, the Molteno3® GDDs have yet to find their rightful place at the top of the market. According to Joe Bankovich, President of Nova Eye Medical, Inc; “We will leverage our existing glaucoma-focused sales and marketing infrastructure to drive improved market penetration of the Molteno3®.”
                              
The Nova Eye Medical team understand Prof Molteno’s groundbreaking research and innovations and the unique advantages of the Molteno3® implants. They are perfectly positioned to strengthen and grow the Molteno3® brand in the global market.
 
Nova Eye Medical has acquired the lease on Molteno Ophthalmic’s cleanroom facility and is retaining the entire manufacturing workforce in Dunedin, New Zealand. Dr Nina Molteno, CEO of Molteno Ophthalmic Ltd, is contracted for a transition period to ensure that production and implant supply continues without interruption and the change in ownership is seamless.

Covid-19 pandemic update: implants available, delivery slowed. - 26th Mar 2020

Covid-19 pandemic update: implants available, delivery slowed. Molteno Ophthalmic was maintaining normal production during the Covid-19 pandemic but changes to the alert level in New Zealand on 25 March to a nationwide state of emergency mean that we are now operating at the lowest level compatible with continued supply of implants to customers and maintenance of our cleanroom environment. Our skilled technical staff are working on a schedule that keeps staff isolated and taking other measures to reduce any risk of infection. Management staff are working remotely. Overseas trips are postponed but training and meetings continue by phone and video link.
Deliveries of Molteno and Molteno3 glaucoma implants to our customers may be slower than usual as the number of aeroplane flights is dramatically reduced worldwide. Please order in good time and maintain good reserves of Molteno and Molteno3 glaucoma implants.
Our thoughts and best wishes are with our customers, their families and friends and the communities affected by significant Covid-19 outbreaks.

Independent study: significant time saving with Molteno3® GDDs compared to Baerveldt® Devices - 23rd May 2019

Dr Sheybani, lead researcher in study comparing Molteno3® and Baerveldt® devices

Ophthalmologists from Missouri, USA, updated the results from their comparison of Molteno3 and Baerveldt glaucoma implant surgery at the recent AGS Annual Meeting [1,2].  The independent study is ongoing and now includes 113 cases. Key findings were:
1.      Surgical time was more than 11 minutes shorter in the Molteno3 group [1]
2.      IOP, vision change and medication use were equivalent after surgery, despite the smaller area of Molteno3 implants.

In a subsequent interview by Dr Davinder Grover, lead investigator, Dr Arsham Sheybani, added that
1.    patient comfort is better during Molteno3 surgery
2.    Molteno3 implantation requires less manipulation of the extra-ocular muscles
3.    the more pliable Molteno3 tubes require only one relieving slit (compared to two slits in the Baerveldt tube) and
4.    Molteno3 surgical time was shorter despite residents and fellows (trainees and less experienced ophthalmologists) performing many of the surgeries.

This is the first reported study comparing surgical time between Molteno3 and Baerveldt devices. Shorter surgical time is better for the patient, saves surgeon time and significantly reduces costs: one more reason to choose the advanced Molteno3 glaucoma drainage devices for patients with severe or complex glaucoma. 
 

References:
1. Maxwell W. Dixon, Joel Palko, Arsham Sheybani; Comparing the Baerveldt and Molteno Shunts for Treatment of Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2076.  
2. Maxwell W. Dixon, Mathew S. Margolis, Joel Palko, Arsham Sheybani; Differences in Intraocular Pressure and Medication Usage between the Baerveldt and Molteno Glaucoma Drainage Devices. Poster presented at the  American Glaucoma Society 2019 Annual Meeting.

World Glaucoma Week 2019 - 12th Mar 2019

World Glaucoma Week 2019 Early detection of glaucoma saves sight! World Glaucoma Week is a gentle reminder to have your eyes checked regularly. Guidelines suggest an eye check every 5 years from the age of 45. Start eye checks at a younger age if there is a family history or other risk factors such as steroid treatment. 

You may not know you have glaucoma as many types of glaucoma cause few symptoms. People are adaptable and the gradual loss of peripheral vision may not be noticed. Early detection and treatment can prevent losing vision to glaucoma.

Having a relative with glaucoma increases your chances of having glaucoma yourself. Remind family members to have an eye check. An eye check to detect glaucoma generally includes:

  • a test of the visual fields
  • measurement of intra-ocular pressures
  • an examination of the optic discs.
Don't delay, book an eye check today!

World Glaucoma Week is a joint initiative between the World Glaucoma Association and the World Glaucoma Patient Association.

Molteno Ophthalmic takes a summer vacation - 11th Dec 2018

Molteno Ophthalmic takes a summer vacation MOLTENO Ophthalmic has had a busy year. Highlights of 2018 include:

  • exhibiting at major international glaucoma congresses in America, Asia and Europe,
  • participating in large international tenders,
  • a new distributor portal and enhanced distributor support.
  • exciting developments in our R&D projects.
The manufacturing and management teams are taking a summer break to rest and refresh themselves for 2019. 

Customers are encouraged to check stock levels and place orders for Molteno and Molteno3 Glaucoma Drainage Devices by 16th December 2018. 

We wish you a very Merry Christmas and a Happy New Year!

 

Did you know? Historical facts about glaucoma surgery #1: - 11th Oct 2018

Absorbable suture occluding the tube of a Molteno3 implant

In the 1970s a two-stage surgery was developed to prevent hypotony [1]. In the first surgery the plate of the implant was sutured onto the globe beneath Tenon’s tissue, then, in a second surgery 8 weeks later, the tube of the implant was inserted into the anterior chamber (AC). Between the first and second surgeries a thin layer of collagen was laid down in the wall of the bleb (the tissues around the plate) [2]. When the aqueous started draining from the AC, up the tube and into the bleb, the thin layer of collagen prevented hypotony by acting as a flexible barrier.

Unexpectedly, the two-stage surgery also resulted in much less bleb fibrosis and better IOP control. Keeping aqueous out of the bleb for 8 weeks was very beneficial. This technique became known as ‘delayed drainage’.

When Vicryl™(polyglactin) sutures were developed, the two-stage procedure was replaced by a single surgery [3]. At the time of surgery a 5.0 Vicryl suture was tied around the tube, completely blocking all flow. 5.0 Vicryl dissolves after 4-6 weeks so there was a 4-6 week delay before aqueous started to drain into the bleb. This produced similar results to the 8 week two-stage procedure.

Vicryl is a trade mark of Ethicon Inc.

References:
1) Molteno ACB, Van Biljon G, Ancker E: Two-stage insertion of glaucoma drainage implants . Trans Ophthalmol Soc NZ 1979;31:17-26.
2) Molteno AC, Fucik M, Dempster AG, Bevin TH. Otago Glaucoma Surgery Outcome Study: factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmology. 2003 Nov 1;110(11):2198-206.
3) Molteno AC, Polkinghorne PJ, Bowbyes JA. The vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma. Australian and New Zealand journal of ophthalmology. 1986 Nov;14(4):343-54.

Molteno Ophthalmic celebrates EN ISO 13485:2016 - 13th Sep 2018

Molteno Ophthalmic staff celebrate meeting the EN ISO 13485:2016 quality standard. Molteno Ophthalmic staff enjoyed a celebratory lunch after a successful audit by DEKRA earlier in the week.
The company's quality management system and implementation meets the requirements of EN ISO 13485:2016, updating our previous EN ISO 13485:2012 certificate.
Particular thanks to Janine Hunter for her hard work as Quality Assurance Manager and to our dedicated staff for their commitment to quality at every step of Molteno and Molteno3 glaucoma drainage device manufacture. 

Molteno3 S-Series glaucoma implants launch in Greece - 16th Jun 2018

The 24th Greek Glaucoma Congress held in Athens was a hive of happy activity as ophthalmologists from Greece and further afield gathered to learn about new developments. Keynote speaker, Prof Mark Sherwood (Florida), an experienced Molteno3 surgeon, addressed the topics ‘Trabeculectomy versus Tube as Primary Procedure’ and ‘New Approaches to Glaucoma Surgery’. Greek surgeons are excited about the Molteno3 S-Series implants, particularly the versatile Molteno3 SS (185mm2) model.  Molteno3 S-Series implants are available from Erghani SA, a specialist ophthalmic distributor.
Erghani SA, in conjunction with Alfa-Intes and MOLTENO Ophthalmic, arranged high-level training in Bologna, Italy for leading glaucoma surgeons so that patients get the best outcomes from Molteno3 surgery. After very positive feedback, further training courses are planned to meet the demand.
Dr Nina Molteno, chief executive at MOLTENO Ophthalmic, travelled to Athens to train the Erghani staff and to meet with the Greek surgeons. She was very impressed by the enthusiasm and dedication of the ophthalmologists, nurses, administrators and the Erghani staff. Those working in government-funded settings are providing ophthalmic services to their patients on extremely tight budgets, yet the clinics were spotless, the staff friendly and the service seemed very efficient. MOLTENO Ophthalmic is proud to be helping such dedicated professionals to save vision and improve the lives of glaucoma patients.  
 




Molteno® Ophthalmic Limited
PO Box 6322 Dunedin
New Zealand

Phone: +64 3 479 2744
Fax: +64 3 479 2444
Email: sales@molteno.com

site map | privacy statement | About | Contact
 

Subscribe

RECEIVE UPDATES
FROM MOLTENO®

site powered by - Turboweb :: Simple Web Manager